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Abstract  
Background: Early cART reduces mortality and morbidity in HIV-infected children. 
Cytopaenias may develop in HIV-infected individuals, contributing to poor outcomes and few 
descriptions of cytopenias are available in children.  
Objectives: Describe the prevalence and outcomes of cytopaenias at baseline (cART 
initiation) and 6 and 12 months in HIV-infected children at Chris Hani Baragwanath 
Academic Hospital.   
Methods: Electronic and paper-based records of HIV-infected children under 3 years of age 
and initiating cART between the 1
st
 January 2010 and 31
st
 December 2012 were reviewed. 
Anthropometric measurements, clinical characteristics and laboratory findings at baseline, 6 
and 12 months of cART were collected for analysis and compared at each outcome.   
Results: At baseline, the 185 HIV-infected children eligible for this study had a median age of 
13 months (range 1 – 36), with advanced disease: 44% were underweight and stunted, 31% 
were wasted; 92% had WHO stage III/IV, CD4 count <15% in 36% and 85.5 % had a viral 
load ≥100 000 copies/ml. The median haemoglobin was 9.9 g/dl, white cell count 11.8 x 
10
9
/L and platelet count 354 x 10
9
. Anaemia, thrombocytopaenia and leukopaenia were 
present in 80%, 6.9% and 1.2% of children respectively. At 6 months the proportion of 
children with anaemia decreased to 46% (p<0.001) and 32% (p<0.001) at 12 months after 
cART; and thrombocytopaenia decreased to 1.9% (p<0.320) and 0.86% (p=0.017).  
Conclusions: The majority of HIV-infected patients are anaemic at baseline. This study 
shows that at 6 and 12 months, there is significant reduction in anaemia and 
thrombocytopaenia, likely related to cART.  
Study  clearance certificate:  Human research ethics committee (Medical) number M131042  
Funding: investigator initiated study with no funding 
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 1 
Introduction 
1.1 Background 
The human immunodeficiency virus (HIV) belongs to a large family of related retroviruses, 
known to cause immunodeficiency. In Africa 23 million people are HIV-infected constituting 
about 70% of the world’s burden.1 South Africa is one of the most severely affected countries, 
with more than 6 800 000 [6 500 000 - 7 500 000] infected persons.
2 
 With current Prevention 
Mother To Child Transmission (PMTCT) Programmes, transmission rates at the 6 week PCR 
test are around 2.4 % according South African Prevention Mother To Child Transmission 
effectiveness (SAPMTCTE).
3
 Recently NHLS, through the District Health Barometer 
reported data showing that the early vertical transmission rate in South Africa for 2013/14 is 
was 2.2%, slightly lower. Over the past few years (2011-2014), the national average for 
Antenatal HIV prevalence was around 29.5%, with KwaZulu-Natal with highest and Northern 
Cape with lowest prevalence,
4
 approximately 60 000 infants were born with HIV infection, 
and total of 360 000 children less than 15 years of age were living with HIV infection.
5  
Early combination antiretroviral therapy (cART) initiation in children, particularly those 
under 12 months has been included in local and international guidelines since 2010, based on 
findings from the CHER study which showed a 76% reduction in mortality in children 
initiating cART before they became symptomatic.
6
 Despite this, less than half of children in 
South Africa who need cART, receive it. Treatment coverage for children remains a priority 
in South Africa and sub-Saharan Africa. In addition, the region needs to scale up programmes 
to diagnose, treat, and provide care and support to children living with HIV who have 
survived through childhood into their teens.
7
 Without early cART, disease progression may be 
rapid in young children and over 50% of children perinatally infected will die before their 
second birthday. (Marston) Immune deterioration and Acquired immune deficiency syndrome 
(AIDS) is caused by the human immunodeficiency virus (HIV) and is characterized by 
progressive damage to immune system, which results in a number of opportunistic infections, 
immunological and haematological complications. The main immunological complication and 
hallmark of HIV infection is cellular CD4 T-lymphocyte depletion for which various 
mechanisms: HIV induced cytolysis; dysregulation of cytokines; cytotoxic T-lymphocyte 
responses and HIV- induced autoimmune reactions, all of which may co-exist. 
Haematological complications are the second most common cause of morbidity and mortality 
in HIV-infected individuals and are characterised by cytopaenias such as anaemia, 
lymphopaenia, neutropenia, and thrombocytopaenia.
8 
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The full blood count (FBC) measures these abnormalities and a panel of tests examining 
whole blood includes the following: total white blood cell count (WBC) and differential 
count, red blood cell count (RBC), haemoglobin concentration (Hb), hematocrit (Hct), platelet 
count (Plt), red cell indices including mean corpuscular volume (MCV), mean corpuscular 
haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), and red cell 
distribution width (RDW).
9 
Abnormalities of the FBC may result in clinical symptoms and 
signs such as weakness, fatigue, fever or bruising. The FBC may also diagnose conditions/ 
diseases such as anaemia, infection, and other disorders and additionally may be used to 
determine the stages of a particular disease.
 
The FBC may provide evidence of infection and 
may assist with monitoring the response to treatment, usually a leukocytosis in children with 
an initial neutrophilic response to both bacterial and viral infections. If significantly abnormal 
FBC values are obtained, a peripheral blood smear should be prepared and examined (e.g., red 
cell morphology, WBC differential, platelet count estimation, identification of immature 
cells).
5 
Haematological abnormalities have been reported in HIV infected children and adults pre- 
and post-introduction of CART. These haematological manifestations of HIV are common 
and diverse, occurring in all stages of infection. Cytopaenias are one of the most common 
complications of HIV and may be broadly classified as being due either to a bone marrow 
production defect associated with chronic illness or to increased peripheral loss or destruction 
of blood cells by the HIV virus itself, adverse effect of medications such as (zidovudine) or 
medications to treat opportunistic infections (ganciclovir) and nutritional status.
10 
Anaemia is the most common cytopaenia and occurs in up to 95% of HIV-infected patients 
during their disease course, which may be due to haemolysis or bone marrow suppression. 
The main mechanism of anaemia of chronic disease is a disturbed bone marrow cytokine 
homeostasis. HIV is cytotoxic to T-helper lymphocytes, which in turn leads to dysregulation 
of B cells and altered release of cytokines. HIV-infected T cells directly suppress growth of 
bone marrow progenitors, thus suppressing haemopoeisis. CD4, the cell-surface receptor 
target of HIV, is carried by T-helper lymphocytes, monocytes and microvascular endothelial 
cells, which are prevalent in marrow.
11 
Combination ART is an important intervention in cytopaenic HIV patients, as it reduces the 
cytokine disturbances. However, if patients develop a new cytopaenia while taking cART, 
then a drug-induced cytopaenia must be considered and a change of cART regimen may be 
required.
12 
There is a risk of anaemia among HIV-infected children on antiretroviral therapy 
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containing zidovudine (AZT) a drug associated with bone marrow suppression and is 
recommended in first-line regimens in the WHO guidelines.
13
 Thus current SA guidelines 
recommend a baseline FBC and repeats only if receiving AZT on the 1
st
, 2
nd
 and 3
rd
 month.
14
 
In the literature the haematological abnormalities of HIV are commonly described in adults 
and they are a significant cause of morbidity and mortality. Early intervention with cART is 
vital in correcting the haematological abnormalities. Descriptions of haematological 
abnormalities in HIV infected children are less frequent, particularly in the current era of 
earlier cART initiation. A study of children from Rural Uganda in November 2007 to June 
2009 described a high prevalence of anaemia at ART initiation occurring in 57.6% of 
participants. Anaemia is associated with low CD4 count, young age and advanced WHO 
clinical disease.
15
 Anemia is the most common hematological abnormalities in HIV patients 
and it is a wide spread public health problem. The World Health Organization estimates that 
over 2 billion people are anemic worldwide with more than 100 million of these anemic 
children living in Africa.
16
 
 It has been suggested that the impact of age at infection may be due to background mortality 
patterns.
17
 Anaemia is associated with increased mortality in infants hence starting ART very 
early reduces disease progression and early mortality. Children with low haemoglobin level 
and delayed development shall get proper diagnosis and care such as nutritional interventions 
and cotrimoxazole prophylaxis should be initiated as early as possible to all eligible infants 
and children to reduce early mortality to reduce the risk of death.
18
  
Given the paucity of data in young HIV-infected children regarding cytopaenias in the era of 
early cART initiatuion, this study sought to describe the prevalence and outcomes of 
cytopaenias at baseline (cART initiation) and 6 and 12 months in HIV-infected children at 
Chris Hani Baragwanath Academic Hospital. 
1.2 Study approval 
The study was approved by the Human Research Ethics Committee (Medical) of the 
University of Witwatersrand, clearance certificate number M1313042. Permission to conduct 
research was approved by the medical advisory committee of Chris Hani Baragwanath 
Hospital.  
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2.0 METHODS 
2.1 Study design: This report was a retrospective descriptive study 
2.2 Study setting, population and period: Harriet Shezi HIV Children’s Clinic (HSCC) is a 
secondary/tertiary level HIV clinic at Chris Hani Baragwanath Academic Hospital (CHBAH) 
that cares for HIV-infected paediatric patients that are referred from inpatient wards and 
surrounding clinics as result of HIV related comorbidities. Medical care, drugs and laboratory 
testing (including viral load testing) are provided at no cost to patients. Routine medical care 
includes a clinical assessment and HIV staging according to WHO at the initial visit. In this 
study HIV infected children under 3 years of age attending HSCC, CHBAH, Soweto from 1
st
 
January 2010 and 31
st
 December 2012 with confirmed HIV infection were included. Testing 
was according to the guidelines at the time of diagnosis.
19
 Children were eligible if they had a 
full blood count (FBC) done within 3 months of each study period including baseline (cART 
initiation), 6 months and 12 months. Combination ART regimens were selected according to 
guidelines at the time. All children received abacavir, lamivudine and lopinavir/ritonavir 
(LPV/r) unless there was any contra-indication to this regimen. Children co-treated with 
rifampicin-based tuberculosis treatment received additional ritonavir or double dose LPV/r. 
2.3 Study definitions 
Full blood count abnormalities in children were defined as follows: white cell count (< 4.0 or 
> 10 ) X 10
9
 cells/microliter, haemoglobin < 11g/dl (-2 SD for age) or > 20g/dl and platelet 
count < 150 000 or > 450 000 X10
9 
  cells/microliter. Baseline defines FBC values of HIV 
infected in the study population prior initiation of cART. 
2.4 Data collection and analysis 
Data was collected from the HSCC database through Therapy Edge Medical Data System and 
file reviews were captured in MS Excel. Data was collected at baseline, 6 months and 12 
months after cART initiation.  Data collected included demographic information (age, sex, 
race), anthropometrical parameters including weight and height for age, clinical including 
WHO staging, significant clinical findings or diagnosis, immunological including CD4 
absolute count and percentage, viral load as well as haematological test results during the 
study period. The captured data from microsoft excel spreadsheet was imported to statistical 
software where medians, means and proportions were calculated using Statistica. ANOVA 
was used to compare means at various time points.  The haematological findings and the key 
 5 
outcomes are reported in percentages along the 95% confidence intervals and significance 
using p-values comparing baseline, 6 months and or 12 months. 
2.5 Sample size 
A sample size calculation based on a preliminary audit of 45 paper-based records of infected 
children fitting the inclusion criteria were reviewed for the prevalence of cytopaenia, and 
found that 20/ 45 (44%) of children had anaemia, far greater than those with 
thrombocytopaenia and leukopaenia. This proportion was used to calculate the sample size Z
2 
(1-p)(p)/d
2
, and of note Z=1.96 & d=0.05 and an estimated sample size of 376 children to 
attain a targeted power of 80% was calculated. However, only 185 children in the clinic over 
the study period met eligibility criteria and could be included. 
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3.0 Results 
3.1 Overall  
Figure 3.1 Shows total number of children files that initiated cART in the study period 
down to those that fitted the inclusion criteria. 
                                                   
 
 
 
      
 
 
 
 
 
 
 
The 185 HIV-infected children eligible for this study had a mean age of 13 months (range 1– 
36) (Figure 3.1). At baseline 44% were underweight and stunted, and 31% were wasted (table 
3.1). According to clinical staging, 92% were WHO stage III and IV and 75% of children 
presented with infection, 60% of which were lower respiratory tract infections. The CD4 
count was <15% in 36%, and 85.5 % had viral load ≥100 000 copies/ml (table 3.2). 
 
 
443 children initiating 
cART in the study period 
400 children’s files reviewed 
185 children included in 
analysis 
Files not found 
N=43 
Did not meet 
inclusion criteria 
N=215 
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Table 3.1 Age, sex, anthropometry, Clinical features or diagnosis, World Health Organization 
(WHO) staging of HIV infection of children at baseline (n= 185) 
 Number of patients (%) 
Age in months, mean (SD) & Range 
<12 
≥12 
Sex: Male 
        Female 
Weight in kg, mean (SD)  & Range   
 Normal (≥ -2 WAZ) 
Underweight (<-2 WAZ) 
Length in cm, mean (SD) & Range 
Normal (≥ 2 HAZ) 
Stunted (<2 HAZ) 
Weight for Length: Normal (≥-2 WLZ) 
                                 Wasted (<-2 WLZ)      
General   
Failure to thrive 
Encephalopathy 
Eczema 
Infections 
Pulmonary TB 
Community acquired pneumonia 
Extra pulmonary 
Pneumocystis Carinii pneumonia 
Other (CMV, Septicaemia, LIP, meningitis, BCG adenitis) 
WHO stage: Stage I/II 
                     Stage III/IV 
14.8±9.5 (1-36) 
78 (42.2) 
107 (57.8) 
93 (50.3) 
92 (49.7) 
7.84±2.54 (2.64-14.20) 
104 (56) 
81 (44) 
71.1±9.7 (46.0-90.0) 
104 (56) 
81 (44) 
128 (69) 
56 (31) 
45 (24.3) 
39 (21.1) 
4 (2.2) 
2 (1.1) 
140 (75.7) 
55 (75.7) 
44 (23.8) 
24 (13.0) 
6 (3.24) 
11 (5.9) 
15 (8.1) 
170 (91.9) 
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Table 3.2 Proportion of HIV infected children with leukopaenia or leukocytosis, anaemia, 
thrombocytopaenia, absolute CD4 count, CD4 percentages and HIV viral load of HIV-infected 
at baseline  
Variable at baseline Number (%) Ranges 
Haemoglobin (Hb) (g/dL) (Mean ± SD) 
Anaemia (Hb <11 g/dL) 
Normal (Hb =11-16 g/dL) 
Polycythaemia (Hb>16 g/dL) 
White cell count (wcc) (x 10
9
/L) (Mean ± SD) 
Leukopaenia (wcc <4x 10
9
/L) 
Normal (wcc = 4-11x 10
9
/L) 
Leukocytosis (wcc >11x 10
9
/L) 
Platelets (Plt) (x10
9
/L) (Mean ± SD) 
Thrombocytopaenia (Plt <150x 10
9
/L) 
Normal (Plt= 150-450x 10
9
/L) 
Thrombocytosis (Plt >450x 10
9
/L) 
Median Absolute CD4 counts (x10
6
/L) 
         < 100 
         100-349 
         350-749 
         >750 
Median CD4 count percentage 
         <15% 
         16-25% 
         >25% 
Median HIV Viral load 
         <1000 
         1000 -99 000 
         ≥100 000 
9.89 ± 1.59 
140 (80.0) 
34 (19.4) 
1 (0.57) 
11.8 ± 5.9  
2 (1.16) 
104 (60.5) 
66 (38.4) 
354 ± 133 
12 (6.86) 
122 (69.7) 
41 (23.4) 
1389 
6 (3) 
28 (16) 
47 (26) 
100 (55) 
28 
65 (36) 
59 (33) 
57 (31) 
741690 
3 (1.7) 
31 (17.8) 
140 (80.5) 
2.74-16.6 
 
 
 
2.43-34.5 
 
 
 
6-730 
 
 
 
2-4752 
 
 
 
 
3.8 - 61 
 
 
 
40-23600000 
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At baseline the prevalence of haematological abnormalities in HIV infected children were as 
follows- anaemia 80%; leukocytosis 38%, thrombocytosis 23%,  thrombocytopaenia 7% and, 
leukopaenia 1%. At baseline anaemia was present in 80% of children, with a mean value of 
9.78 g/dl, improving to a mean 10.9 g/dl at 6 months and 11.3 g/dl at 12 months (p-value 
<0.001 respectively). There was no difference in mean platelet levels at baseline, with a mean 
of 346 000 X 10
9 
cells/microliter, compared to 371 000 X 10
9 
cells/microliter at 6 months and 
375 000 X 10
9 
cells/microliter at 12 months with (p= 0.32 and 0.19 respectively). The 
proportion of children with anaemia improved to 45.8% at six and 32.2% at 12 months 
(p=<0.001). Thrombocytopaenia was present in 6.9% of children at baseline, 1.93% at 6 
months (p=0.32) and 0.86% at 12 months (p=0.017). At baseline the mean WCC was 11.8 X 
10
9 
cells/microliter, 1% of children had leucopenia, improving to 0.5% at 6 months (table 
3.3). 
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Table 3.3 Proportion of patients who had leukopaenia or leukocytosis, anaemia and 
thrombocytopaenia at baseline compared to after 6 and 12 months of treatment (cART) 
Variable No. of 
patients 
(%) at  
baseline 
No. of 
patients 
(%) after  
6  
months of 
cART 
No. of 
patients 
(%) after 
12 
months of 
cART 
Baseline 
vs 6 
months 
Baseline 
vs 12 
months 
Haemoglobin (Hb) (g/dL) 
Anaemia (Hb <11 g/dL) 
Normal (Hb =11-16 g/dL) 
Polycythaemia (Hb>16 g/dL) 
White cell count (wcc) (x 10
9
/L) 
Leukopaenia (wcc <4x 10
9
/L)  
Normal (wcc = 4-11x 10
9
/L) 
Leukocytosis (wcc >11x 10
9
/L) 
Platelets (Plt) (x10
9
/L) 
Thrombocytopaenia (Plt <150) 
Normal (Plt= 150-450) 
Thrombocytosis (Plt >450) 
9.78 ±1.55 
140 (80.0) 
34 (19.4) 
1 (0.57) 
11.7 ±6.2  
2 (1.16) 
104 (60.5) 
66 (38.4) 
346 ±148 
12 (6.86) 
122 (69.7) 
41 (23.4) 
10.9±1.3 
76 (45.8) 
90 (54.2) 
0 (0) 
10.1 ±4.2 
1 (0.64) 
102 (65.4) 
53 (34.0) 
371±106 
3 (1.93) 
120 (77.4) 
32 (20.6) 
11.3 ±1.0 
39 (32.2) 
82 (67.8) 
0 (0) 
9.91±3.7 
0 (0) 
82 (70.1) 
35 (29.9) 
375±108 
1 (0.86) 
86 (74.8) 
28 (24.3) 
<0.001 
<0.001 
 
 
<0.001 
0.387 
 
 
0.319 
0.032 
<0.001 
<0.001 
 
 
0.006 
0.500 
 
 
0.189 
0.017 
 
The secondary outcomes shown (table 3.4) anthropometrical improvements  at 6 and 12 
months with around 44% of children underweight at baseline, improving to 21% at 6 months 
and  14% at 12 months (p-value<0.001).  Length for age at baseline showed less recovery 
with similar numbers of children stunted at each time point. Weight for length also showed 
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improvement with 21% of children wasted at baseline, improving to 12% at 6 months, 
maintained through 12 months (p-value =<0.001). 
Table 3.4 Nutritional growth parameters from baseline to 6 and 12 months of cART  
 Number of 
patients 
(%)  at 
baseline 
Number of 
patients (%) 
after 6 
months of 
HIV 
treatment 
Number of 
patients (%) 
after 12 
months HIV 
of treatment 
Compariso
n between 
baseline 
and 6 
months (p-
values) 
Compariso
n between 
baseline 
and 12 
months (p-
values) 
Weight  
Normal 
Underweight          
Length   
Normal 
Stunted 
Weight for length 
Normal 
Wasted 
 7.84±2.55 
104 (56) 
81 (44) 
71.1±9.7 
104 (56) 
  81 (44) 
 
129 (69) 
  56 (21) 
9.85±2.26 
143 (79) 
  36 (21) 
77.3±7.6 
102 (56) 
78 (44) 
 
163 (88) 
17 (12) 
11.3±2.04 
126 (86) 
  21 (14) 
82.12±6.3 
76 (52) 
71(48) 
 
139 (88) 
 8 (12) 
 
<0.001 
<0.001 
<0.001 
 
0.930 
 
<0.001 
 
<0.001 
<0.001 
<0.001 
 
0.412 
 
<0.001 
 
CD4 absolute count and percentage improved significantly on cART, with CD4 absolute 
count and percentage increasing from  baseline 976 cells/mm
3 
and 20%  to 1586 cells/mm
3
 
and 28% at 6 months and 1721 cells/mm
3 
and 30% at 12 months follow up (p=< 0.001) (Table 
3.5). The viral load copies reduced from a mean of 741690 copies/ml at baseline to 327.5 
copies/ml at 6 months and 125 copies/ml at 12 months as shown in table 3.5. Despite this 
steady improvement, the proportion of children with viral loads < 1000 copies/ml at 6 months 
was 36.7%  and at 12 months 43.2% (p=< 0.001).  
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Tabl 3.5 Comparisons in changes in CD4 absolute counts, CD4 percentages and HIV viral load 
at baseline and after 6 months and 12 months of cART 
Variable Number of 
patients (%)  
at baseline 
 
Number of patients 
(%) after 6  
months of  cART  
Number of 
patients (%) after 
12 months of  
cART 
Compa
rison 
between 
baseline 
vs 6 
months 
Compa
rison 
between 
baseline 
vs 12 
months 
CD4 Absolute Count (x10
6 
/L) 
< 100 
100-349  
350-749 
>750   
CD4 Percentage 
<10% 
10-15% 
16-25% 
>25% 
Viral load copies/ml median 
(Range) 
< 1000 
1000 – 99 000 
≥100 000 
976±742 
6 (3) 
28 (16) 
47 (26) 
100 (55) 
20.3±11.7 
31 (17) 
34 (19) 
59 (33) 
57 (31) 
741690 (40-
23600000) 
3 (1.7) 
30 (17.3) 
140 (81.0) 
1586±917 
1 (1) 
3 (2) 
17 (10) 
146 (87) 
28.0±9.8 
5 (3) 
13 (7) 
47 (26) 
102 (56) 
327.5 (40-8832505) 
61 (36.7) 
67 (40.4) 
38 (22.9) 
1721±782 
0 (0) 
0 (0) 
8 (6) 
125 (94) 
30.6±9.8 
1 (1) 
6 (4) 
33 (25) 
93 (70) 
125 (40-8832505) 
61 (43.2) 
62 (44) 
18 (12.8) 
<0.001 
0.062 
 
 
 
<0.001 
<0.001 
 
 
 
<0.001 
<0.001 
<0.001 
0.040 
 
 
 
<0.001 
<0.001 
 
 
 
<0.001 
<0.001 
 
3.2 Discussion 
In this study over 80% of HIV infected children have anaemia at baseline, which improves to  
45.8% at 6 months and 32% at 12 months after cART initiation.  Abnormalities in the other 
cell lines were less impressive at baseline with 6.9% having a  thrombocytopaenia improving 
to 1.9% at 6 months and 0.9% at 12 months;  and leukopaenia at baseline 1.2% improving to 
0.6% at 6 months and none at 12 months after cART initiation. After 6 months of being on 
treatment the mean haemoglobin value improved significantly to 10.9 g/dl, p value <0.001 
 13 
and the mean white cell count improved from baseline to 6 months p value <0.001 with not 
much difference at 6 and 12 months whereas mean platelets value remained normal at 
baseline, 6 months and 12 months after cART initiation. These findings are similar to those 
from a Belgian in 2001 by J Servais et al and also the recent Kenyan study of 2015 by EG 
Kibaru showing improvements in  HIV associated haematologic disorders in adults at 6 
months after cART initiation.
20,21
 Multiple factors contribute to haematological abnormalities 
and each case needs careful consideration, with a meticulous, logical approach, including 
consideration of all possible contributors such as haematinic deficiencies and bone marrow 
infiltration.
12 
The improvements in anaemia may have been due to a number of factors 
including treatment of infections, receiving supplementation with folate and iron and of 
course cART itself. Additionally, children accessing health care at HSCC may have been 
referred for nutritional support, may have been referred to access financial grant support 
which may have improved the family’s nutritional and socioeconomic situation. 
Children receiving cART also demonstrate improvement of other clinical and immunological 
parameters over time. Anthropometrically, there is an improvement in WAZ at each timepoint 
and for WFH improvement at 6 months which then plateaus at 12 months. At baseline there 
was stunting and underweight in 44% of children each, and wasting in 12% all which 
improved at 6 months except for the stunting and this is shown in other studies including the 
2012 South African study by K Meera et al and Meyers et al in 2012 where the mean WAZ 
increased rapidly from −2.40 (95% CI: −2.48, −2.33) at baseline, to −1.40 (95% CI: −1.46, 
−1.33) at 12 months and continued to improve to −1.18 (95% CI: −1.29, −1.07) at 36 months 
but the improvement in the mean HAZ was less impressive, plateauing over time.
22,23
 
Additionally, Mary-Ann Davies at al showed an improvement in nutritional status in a 
longitudinal study between 2005 to 2010 where the number of children with WAZ <−3 
decreased from 31 to 28% (p<0.001) over time and other nutritional indices showed similar 
trends.
24
  
Immunologically, the CD4 count mean increased from 20.3% to 28% & 30.6% and the viral 
load copies reduced from a mean of 741690 copies/ml at baseline to 327.5 copies/ml at 6 
months and 125 copies/ml at 12 months as shown in table 3.5. Despite this steady 
improvement, the proportion of children with viral loads < 1000 copies/ml at 6 months was 
36.7%  and at 12 months 43.2% (p=< 0.001) which is concerning but has been described in 
other studies describing viral load outcomes in young children who appear to take longer than 
12 months to suppress virologically.
23
 
 14 
Violari et al from the CHER study in 2008, showed similar immunological and virological 
responses to cART in young children.
 6
 Similarly, Davies et al showed a steady improvement 
in clinical outcomes, immunological outcomes in HIV-infected children, with those with 
severe WHO Stage III/IV disease decreasing from 75 to 62% in 6 months (p<0.001) and those 
with severe anemia decreasing from  12 to 7% (p<0.001). CD4% count also increased with a 
decrease in those with severe immunosuppression from 81 to 63% (p<0.001).
24
  
In summary factors associated with anaemia in HIV infected children were multifactorial in 
nature.
25
 Although our cohort had a high baseline prevalence of anaemia, cART initiation had 
an impact on improving cytopaenias, particularly anaemia and thrombocytopaenia in HIV 
infected children by 6 months, sustained through 12 months. Thrombocytosis and 
leukocytosis were common in this population, resolving over 12 months. There was also a 
significant improvement in nutritional and growth parameters and immunological response 
measured by CD4 count, and a reduction in viral load. This improvement may not only have 
been due to cART but it is also likely that many children would have  received antibiotics and 
adjunctive treatment like multivitamin, folate and iron supplements, nutritional support and 
possible social support through increased access to child support grants. 
3.3 Limitations 
This study has some limitations. Firstly, there was a low total number of HIV infected 
children with baseline data mainly because of missing data elements on a number of variables. 
We were unable to include the number of children calculated by sample size for optimal 
analytical power, 376 children,  but as 185 children were eligible, they were included even 
though this reduced the study power. This is a result of lower numbers of HIV infected 
children with effective PMTCT but also because SA DoH guidelines do not recommend 
follow-up FBC monitoring and children without follow-up FBC results were excluded from 
analysis. 
The data was retrospectively analysed from a data base and paper based records and hence 
was reliant on accurate capturing which was not always the case. Particularly, data on co-
morbidities, concomitant medications such as folate, iron supplementation and antibiotic 
treatment was not always well recorded so may be underrepresented however, the results are 
statistical significant and clinically there is improvement in both primary objectives and other 
outcomes in HIV infected children on cART. 
 15 
3.4 Recommendations 
Current SA NDoH guidelines recommends baseline FBC, repeated at 6 and 12 months if the 
child is receiving AZT and the improvement in each time point is reassuring. Given the high 
numbers of children with anaemia at baseline, it is important that a baseline FBC remains a 
recommendation in guidelines and that possible causes of anaemia are investigated and 
treated  in HIV infected children. Increased effort required to test and diagnose HIV early in 
infants to initiate ART early and prevent associated morbidity and mortality in children.  
3.5 Conclusions   
Anaemia at cART initiation is common, occurring in 80% of children. Once cART was 
initiated an improvement, likely partly due to cART and improved clinical health, along with 
other factors was seen through 6 and 12 months. Additionally, children had improved 
anthropometrical measures, immunological parameters and viral load suppression, 
highlighting the positive impact of cART in young children. Ongoing efforts to diagnose and 
initiate cART early are likely to reduce these baseline cytopaenias improving children’s 
cART outcomes even further. 
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List of abbreviations 
 
AIDS -acquired immunodeficiency disease syndrome  
CHBAH -Chris Hani Baragwanath academic hospital  
DAIDS –division of AIDS 
DNA – deoxyribonucleic acid 
ELISA – enzyme linked immunosorbent assay 
FBC – full blood count  
HAART - highly active antiretroviral treatment 
Hb - hemoglobin concentration  
Hct - hematocrit  
HIV -human immunodeficiency virus  
HSCC - Harriet Shezi HIV children clinic  
MANOVA –multivariate analysis of variance 
MCH - mean corpuscular hemoglobin  
MCHC - mean corpuscular hemoglobin concentration  
MCV - mean corpuscular volume  
NDoH – National department of health 
NHLS - National health laboratory services  
PCR – polymerase chain reaction 
Plt - platelet count  
PMTCT -Prevention Mother to Child Transmission  
RBC - red blood cell count  
RDW - red cell distribution width  
SAPMTCT - South African Prevention Mother to Child Transmission 
SAPMTCTE- South African Prevention Mother to Child Transmission Effectiveness 
SD – standard deviation 
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Background 
  
The human immunodeficiency virus (HIV) belongs to a large family of related retroviruses, 
known to cause immunodeficiency. In Africa 23 million people are HIV-infected constituting 
about 70% of the world’s acquired immunodeficiency disease syndrome (AIDS) burden. 
South Africa is one of the most severely affected countries, currently having more than 5.6 
million infected persons.
1 
In 2009, 29.4 percent of all pregnant women were HIV infected, 
approximately 60 000 infants were born with HIV infection, and total of 330 000 children less 
than 15 years of age were living with HIV infection.
2 
With the current Prevention Mother To 
Child Transmission (PMTCT) programmes, transmission rates at 6 week PCR test are around 
3.5% according South African Prevention Mother To Child Transmission effectiveness 
(SAPMTCTE).
3
 Every day in sub-Saharan Africa, about 1000 children acquire HIV-1 
infection from their mothers. In 2007 it was estimated that 370 000 children became HIV 
infected globally, 270 000 children under 15 years of age died from HIV/AIDS (UNAIDS).
1
 
Almost 90 percent of all HIV infected children live in sub-Saharan Africa (SSA), with an 
estimated 2.2 to 2.3 million HIV infected children of which about 420 000 children are South 
Africans.
1 
 
Earlier HAART initiation in children particularly those under 12 months has been part of 
local and international guidelines since 2010, based on findings from the CHER study which 
showed a 76% reduction in mortality in children initiating HAART before they became 
symptomatic.
4
 Among the estimated 2.2 to 2.3 million children younger than 15 years living 
with HIV in 2011, only 425 000 were receiving treatment. Treatment coverage for children 
must improve as a matter of urgency. In addition, the region needs to scale up programmes to 
diagnose, treat, and provide care and support to children living with HIV who survived 
through childhood into their teens.
5
 
 
Acquired immune deficiency syndrome (AIDS) is caused by the human immunodeficiency 
virus (HIV) and is characterized by progressive damage to the body’s immune system, which 
results in a number of opportunistic infections, immunological and haematological 
complications. The main immunological complication and hallmark of HIV infection is 
cellular CD4 T-lymphocyte depletion for which various mechanisms: HIV induced cytolysis; 
dysregulation of cytokines; cytotoxic T-lymphocyte responses and HIV induced autoimmune 
reactions which are not mutually exclusive have been suggested. Haematological 
complications have been documented to be the second most common cause of morbidity and 
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mortality in HIV patients and are generally marked with cytopenias such as anaemia, 
neutropenia, lymphopaenia and thrombocytopenia.
6 
 
The full blood count (FBC) consists of a panel of tests that examines whole blood and 
includes the following: total white blood cell count (WBC) and white blood cell differential, 
red blood cell count (RBC), hemoglobin concentration (Hb), hematocrit (Hct), platelet count 
(Plt), red cell indices including mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red cell 
distribution width (RDW).
7 
 
The FBC provides important information about the types and numbers of cells in the blood, 
especially red cells, white cells, and platelets. Abnormalities of the FBC may result clinical 
features features such as weakness, fatigue, fever or bruising. The FBC may also diagnose 
conditions/ diseases such as anemia, infection, and other disorders and additionally may be 
used to determine the stages of a particular disease.
 
A FBC is frequently obtained for evidence 
of infection and the initial response to infection, especially children, is leukocytosis with an 
initial neutrophilic response to both bacterial and viral infections. In general, bacterial 
infections are associated with greater neutrophil counts than viral infections. Transient 
lymphopaenia at the beginning of illness and lasting 24 and 48 hours has been described with 
many viral infections. If significantly abnormal FBC values are obtained, a peripheral blood 
smear should be prepared and examined (e.g., red cell morphology, WBC differential, platelet 
count estimation, identification of immature cells).
2
 
 
Haematological abnormalities have been reported in HIV infected children 
and or adults’ pre and post introduction of highly active antiretroviral treatment 
(HAART). These haematological manifestations of HIV are common and 
diverse, occurring at all stages of infection. Cytopenias are one of the most 
common complications of HIV and may be broadly classified as being due either to a bone 
marrow production defect associated with chronic illness or to increased peripheral loss or 
destruction of blood cells by the HIV virus itself, adverse effect of medications (zidovudine) 
or medications to treat opportunistic infections (ganciclovir) and nutritional status.
8 
 
Anaemia is the most common cytopaenia and occurs in up to 95% of HIV patients during 
their disease course which may be due to haemolysis or bone marrow suppression. The main 
mechanism of anaemia of chronic disease is a disturbed bone marrow cytokine homeostasis. 
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HIV is cytotoxic to T-helper lymphocytes, which in turn leads to dysregulation of B cells and 
altered release of cytokines. HIV-infected T cells directly suppress growth of bone marrow 
progenitors, thus suppressing haemopoeisis. CD4, the cell-surface receptor target of HIV, is 
carried by T-helper lymphocytes, monocytes and microvascular endothelial cells, which are 
prevalent in marrow.
9
 
 
HAART is an important intervention in cytopaenic HIV patients, as it alleviates the cytokine 
disturbances. However, if patients develop a new cytopaenia while taking HAART, then a 
drug-induced cytopaenia must be considered and a change of HAART regimen may be 
required.
10
 
 
JUSTIFICATION OF THE STUDY 
In the literature the haematological abnormalities of HIV are commonly described in adults 
and they are a significant cause of morbidity and mortality. Early intervention with HAART 
is vital in correcting the haematological abnormalities associated with poor outcome. 
Descriptions of haematological abnormalities in HIV infected children are scarce, particularly 
in the era of earlier HAART initiation. Recently HAART is started much earlier than before, 
the effect of this early HAART on bone marrow has not been well documented regarding 
FBC changes. 
 
STUDY AIM & OBJECTIVES 
a. Aim: 
The aim of the study is to describe the prevalence of haematological abnormalities 
pre-and post HAART in HIV infected children attending Harriet Shezi HIV 
Children Clinic (HSCC), Chris Hani Baragwanath Academic Hospital (CHBAH) 
SOWETO. 
b. Objectives 
1. To describe the baseline demographics and clinical characteristics of HIV 
infected children under the age of three initiating HAART at HSCC. 
2. To describe the prevalence of anaemia, thrombocytopenia and white cell count 
changes in children pre-and post HAART at HSCC. 
3. To determine the changes in anemia, thrombocytopenia and white cell count 
changes of HIV infected children who have been on HAART for 6 months and 
12 months. 
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METHODOLOGY 
a. Study design 
A retrospective observational descriptive study. 
 
b. Study setting  
The HSCC is a secondary/tertiary level HIV clinic at Chris Hani Baragwanath 
Academic Hospital that cares for HIV-infected paediatric patients that are referred 
from inpatient wards and surrounding clinics as result of HIV related comorbidities. 
 
c. Study Population & period 
This study includes HIV-infected children under the age of 3 years attending HSCC, 
CHBAH SOWETO between the 1
st
 January 2010 and 31
st
 December 2012. 
 
Standard of care for HAART initiation : During the study period management of children 
Harriet Shezi children clinic was according to the NDoH Guidelines as follows: 
 1) Children HIV infected (PCR positive) under 1 year of age regardless of CD4 
     or disease stage  
2) Children between 1 to 5 years WHO stage III, IV or CD4 percentage < 25 or 
    absolute count < 750 cells/mm
3
.  
3) Children over 5years WHO stage III, IV or CD4 percentage <15 or absolute 
    count<350 cells/mm
3
.
 11 
(i) Inclusion  criteria 
 Confirmed HIV diagnosis by a positive HIV DNA-PCR test in a child 
under 18 months or a positive HIV ELISA in a child over 18 months of 
age. . 
 Children initiating HAART during the study period with a baseline FBC 
(within 3 months before initiation) and at least 1 repeat FBC done at 6 
months or 12 months or both.   
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(ii) Exclusion criteria 
 HIV infected children under 3 years of age who were already receiving 
HAART before referral HSCC during the study period. 
 
       d.   Definition of haematological abnormalities: 
For this study the criteria for full blood count abnormalities in children is a reading of 
white cell count < 4.0 or > 10 cells/microliter, haemoglobin <11g/dl (-2SD for age) or 
haematocrit < 0.35 (-2SD), haemoglobin > 20g/dl or haematocrit > 0.60, 
lymphopaenia < 3cells/microliter or CD4 < 15% & platelets <150 000  or > 450 000 
cells/microliter.
12 
DAIDS grading tables will be used to grade haematologic 
abnormalities. 
 
       e.   Data collection 
A list of haematological/ laboratory FBC findings from HIV infected children under 3 
years of age initiating HAART will be obtained from HSCC data system. Information 
that will be obtained from this data base, includes the demographic and clinical data, 
such as age, weight, height, sex, race, clinical presentation, clinical diagnosis, CD4 
count and viral load during the study period. 
 
f. Data handling  
            Information obtained from HSCC database will be captured in Microsoft 
            Excel spread sheet and data sheet. In STATA the data sheet will contain 
            FBC results (pre-and post HAART ) limited demographic & clinic data.  
          Anonymity will be ensured, by allocating each case study patient in the 
          data collection sheet a number which will only be linked to patient identifiers 
          in a password protected document. 
 
g. Data processing and analysis 
           Data captured from Microsoft Excel spreadsheet will be imported to statistical 
           software where all data management and statistical analysis will be performed. 
           Appropriate descriptive statistical analysis will be carried out means and 
           standard deviations will be used in continuous variables with normal 
           distribution and median or quartiles will be used for non parametric continuous 
           variables and categorical variables will be described using percentages. 
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           The haemtological findings and other key outcomes will be reported using 
           percentages along with 95% confidence intervals. In comparing the parameters 
           before and after 6months of HAART the T test will be used and in comparing 
           further to include period after 12 months of HAART an MANOVA will be 
           used.  
  
Implication of this study 
This study will provide information to clinicians about the pre-HAART and post-HAART 
FBC abnormalities in HIV-infected children and will provide a description of these 
abnormalities and associated comorbidities. 
 
Challenges 
 For the purpose of this study, haematological abnormalities of the full blood count, only 
includes presence of anemia, thrombocytopenia and white cell count changes. The other full 
blood count abnormalities such as reticulocytes & total red cell distribution width values have 
not been considered. Some or most of the laboratory full blood count results did not include 
differential count. As this study is a retrospective one it might be difficult to obtain all 
required data due to transcription errors in patient file numbers captured incorrectly making it 
difficult finding and retrieving results of FBC or to accessing the laboratory data. 
 
Ethics approval 
This study was approved by: The Human Research Ethics Committee of the university of the 
Witwatersrand and the Ethics clearance certificate number is M131042 and also the hospital 
CEO of CHBAH granted the permission to conduct the study in HSCC and make use of their 
data base. This data will only be used for the purpose of the study. No consent will be 
required from the parents since it is a retrospective study. 
 
Budget 
The cost (transport to & fro, stationery, printing, photocopying & binding) and funding of the 
study will be borne by the researcher +/- R1500. 
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APPENDIX D: DATA CAPTURING SHEET 
 
 
Hospital #: _____________________     TE number: 64-                               
  
Demog 
 
 
Baseline (ART start day) 6months 12months 
Date of Birth  
      Race  
(1=African; 2=Non-African) 
 
Sex (1=Male; 2=female)  
Date of 1st visit 
 
Date HAART started 
Date of Visit       
Age        
Weight (kg)       
Height (cm)       
BMI       
WHO Clinical stage       
CD4 
Absolute       
Percentage       
Date                  
VL 
VL       
VL Date       
FBC 
Wcc       
Hb       
Mcv       
Plt       
Neutrop       
Lymph       
FBC Date        
LFT 
ALT       
AST       
LFT Date       
TB 
AFB       
Culture       
TB Expert        
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Date       
Reactive PPD (Y/N)       
ARV 
(1) abc/3tc/kal 
(2) d4t/3tc/kal 
(3) d4t/3tc/kal/rit 
(4) abc/3tc/kal/rit 
   
Rx 
(1) Bactrim       
(2) MVT        
(3) Anti-TB       
(4) Other        
If  other specify       
 Mom 
PMTCT 
  
(1) Mom-AZT & NVP    
(2) Mom HAART   
(3) None 
      
Child 
PMTCT 
(1) Child-NVP 
(2) Child-AZT & NVP 
(3) None 
      
Feeding 
history: 
(1) Excl breastmilk 
(2) Formula fed 
(3) Mixed feeds 
(4) Unknown 
      
Dx & clin 
pres 
Pneumonia (√)       
PCP/PJP (√)                        
CMV (√)       
GE (√)       
Sepsis  (√)       
MAC (√)    
Parvovirus (√)    
EBV (√)    
Hepatitis B (√)    
Other, specify    
Admin 
Date of completion       
Date of capture       
Captured by       
Comments: 
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APPENDIX E: PLAGIARISM DECLARATION 
 
PLAGIARISM DECLARATION TO BE SIGNED BY ALL HIGHER DEGREE 
STUDENTS 
SENATE PLAGIARISM POLICY:  
 
I, Theodore Mlungisi Mabaso (Student number: 9103081Y) am a student 
 
registered for the degree of   MMED IN PEDIATRICS  in the academic year  2012. 
 
I hereby declare the following: 
 I am aware that plagiarism (the use of someone else’s work without their permission 
and/or without acknowledging the original source) is wrong. 
 
 I confirm that the work submitted for assessment for the above degree is my own 
unaided work except where I have explicitly indicated otherwise. 
 
 I have followed the required conventions in referencing the thoughts and ideas of 
others. 
 I understand that the University of the Witwatersrand may take disciplinary action 
against me if there is a belief that this is not my own unaided work or that I have failed 
to acknowledge the source of the ideas or words in my writing. 
 
Signature: _________________________ Date: ________________________ 
 
 
 
